Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Today marks the first day of #FFN2021! Emmanuel Caeymaex, Head of Immunology & US Solutions and Executive Vice President at UCB, shares his thoughts on the importance of post-fracture care and its impact on patient outcomes. https://t.co/Ry3HspNtrh
— UCB News (@ucb_news) 28.09.2021 -
UCB is question-led, meaning our approach to serving patients begins with questions like, “How can we improve symptoms and how quickly?” Learn about the principles that guide our work from UCB’s Chief Data Officer, Mike Branson https://t.co/NgHC1Gavwu htt
— UCB News (@ucb_news) 27.09.2021 -
We can’t wait to participate in #FFN2021, starting tomorrow! It is estimated that 1 in 3 women aged 50 or over may experience an #osteoporosis related #fracture. Learn more about #fragility fractures and ways of improving patients’ lives and register here
— UCB News (@ucb_news) 27.09.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
